$12.91 2%
DVAX Stock Price vs. AI Score
Data gathered: November 27

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Dynavax Technologies (DVAX)

Analysis generated May 26, 2024. Powered by Chat GPT.

Dynavax Technologies Corporation (DVAX) operates as a biopharmaceutical company focused on leveraging the innate immune system to fight disease. The company develops and commercializes novel vaccines and immune-oncology therapies. Key products include Heplisav-B, a vaccine for hepatitis B, and several other programs in clinical and preclinical development aimed at addressing infectious diseases and cancer.

Read full AI stock Analysis

Stock Alerts - Dynavax Technologies (DVAX)

company logo Dynavax Technologies | November 15
Price is down by -5.6% in the last 24h.
company logo Dynavax Technologies | November 11
Price is up by 5.5% in the last 24h.
company logo Dynavax Technologies | November 8
Price is up by 5.1% in the last 24h.
company logo Dynavax Technologies | October 28
Price is up by 6.4% in the last 24h.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.


Dynavax Technologies
Price $12.91
Target Price Sign up
Volume 658,120
Market Cap $1.66B
Year Range $10.05 - $13.66
Dividend Yield 0%
PE Ratio 84.4
Analyst Rating 100% buy
Industry Drug Manufacturers

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2484M56M28M18M23M0.120
Q2 '2476M54M22M11M18M0.080
Q1 '2451M56M-5.2M-8.7M-8.7M-0.070
Q4 '2357M51M5.8M220,0003.8M0.002
Q3 '2371M51M20M14M17M0.100

Insider Transactions View All

CANO FRANCIS filed to sell 36,905 shares at $11.9.
June 3 '24
Burgess Justin filed to sell 13,425 shares at $12.8.
March 4 '24
Janssen Robert filed to sell 49,925 shares at $15.
January 8 '24
Novack David F filed to sell 3,187 shares at $14.5.
January 4 '24

What is the Market Cap of Dynavax Technologies?

The Market Cap of Dynavax Technologies is $1.66B.

What is Dynavax Technologies' PE Ratio?

As of today, Dynavax Technologies' PE (Price to Earnings) ratio is 84.4.

What is the current stock price of Dynavax Technologies?

Currently, the price of one share of Dynavax Technologies stock is $12.91.

How can I analyze the DVAX stock price chart for investment decisions?

The DVAX stock price chart above provides a comprehensive visual representation of Dynavax Technologies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Dynavax Technologies shares. Our platform offers an up-to-date DVAX stock price chart, along with technical data analysis and alternative data insights.

Does DVAX offer dividends to its shareholders?

As of our latest update, Dynavax Technologies (DVAX) does not offer dividends to its shareholders. Investors interested in Dynavax Technologies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Dynavax Technologies?

Some of the similar stocks of Dynavax Technologies are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.